Sonnemed Patent Filing

(WO/2009/129321) COMPOUNDS AND METHODS FOR ACTIVATED THERAPY

Pub. No.:		WO/2009/129321

Publication Date: 22.10.2009
International Application No.: PCT/US2009/040688
International Filing Date: 15.04.2009

• Description
• Claims
• National Phase
• Notices
• Document

Applicants:
SONNEMED LLC [US/US]; 10 Mt. Vernon Street, #208 Winchester, MA 01890 (US) (All Except US).
LEWIS, Thomas [US/US]; (US) (US Only).
SZULWACH, Ann, M. [US/US]; (US) (US Only).

Inventors:
BURKE, Donald; .
LEWIS, Thomas; (US).

Title:
COMPOUNDS AND METHODS FOR ACTIVATED THERAPY

Abstract:
Provided herein are compounds for detection, diagnosis and treatment of target tissues or target compositions, including hyperproliferative tissues such as tumors, using sonodynamic and/or photodynamic methods. In particular, photosensitizer and/or sonosensitizer compounds that collect in hyperproliferative tissue are provided.

Description
[Snips]
The compounds of the invention are useful as sonosensitizers, photosensitizers and/or as dual acting sensitizers as therapeutic and diagnostic agents, for example for treatment of several cancer types such as, but not limited to, melanoma, prostate, brain, colon, ovarian, breast, skin, lung, esophagus and bladder cancers and other hormone-sensitive tumors, as well as for treatment of age-related macular degeneration, and for killing cells, viruses, fungi and bacteria in samples and living tissues as well known in the art of PDT and other sonosensitizer applications.
....

The invention further relates to a method of sonodynamic therapy, which comprises administering to an individual in need an effective amount of a compound of the invention, followed by local ultrasound. The compounds of the invention are also useful for photo- and sonodestruction of normal or malignant animal cells, as desired, as well as of microorganisms in culture, enabling selective photo- and sonodestruction of certain types of cells in culture or infective agents. Thus, the invention further provides the use of the compounds of the invention for in vivo, ex-vivo or in vitro killing of cells or infectious agents such as bacteria, viruses, parasites and fungi in a biological product, e.g. blood, which comprises treating the infected sample with the compound of the invention followed by ultrasound of the sample. Examples of such diseases or conditions include acne, Aids, viral hepatitis, diabetic retinopathy, infection with sars virus, coronary artery stenosis, carotid artery stenosis, intermittent claudication, or Asian (chicken) flu virus, or infections caused by intracellular infectious agents such as Clamidia, tox, ricetzia, rocky mountain spotted fever, q-fever, and others.

Source

Posted by donpatent at 2:24 PM

See also United States Patent Application 20090275548

Primary clinical use of sonodynamic therapy (SDT) for advanced breast cancer

Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 26, No 15S (May 20 Supplement), 2008: 12029
© 2008 American Society of Clinical Oncology

Abstract

X. J. Wang, D. Mitchell and T. J. Lewis

Liu Hua Qiao Hospital, Boston, MA; Opal Clinic, Victoria, Australia; SonneMed, LLC, Boston, MA

12029

Background: There are increasing data showing that sonodynamic therapy (SDT), which refers to a synergistic effect of drugs and ultrasound, is a promising new modality for cancer treatment. Recently a new sonosensitizing agent has been developed by SonneMed, LLC. It is extremely sensitive to ultrasound. As with photodynamic sensitizers, it is specifically absorbed into tumor cells and produces singlet oxygen upon interaction with the right frequency and intensity of ultrasound. The singlet oxygen is able to create cellular necrosis. Our animal studies showed that SDT with SF1 inhibits growth of mouse S-180 sarcoma. Here we report initial clinical data using SDT with SF1 for advanced breast cancer. Methods: Three patients with metastasized pathologically proven breast carcinoma were studied. Their carcinoma failed to respond to conventional therapy and spread to the whole body. The SDT agent was provided through lingual absorption. After 24h, light and ultrasound was applied, irradiating the tumour area for 20 minutes daily for 4 days and repeated every two weeks. Results: Case 1 had breast carcinoma which spread to the whole body. She had surgery, chemo, RT, hormone, Herceptin, Zometa etc, but all failed. The tumor kept growing until she multiple acute symptoms. After 3 SDT treatments her symptom improved significantly and windpipe spile, gastric and urine catheter were all taken off. PET/CT scans showed a positive partial result (PR). Case 2 had left breast carcinoma with multi-organ metastases. After 2 treatments PET/CT scan showed very positive PR. PET/CT taken 28 months after treatment showed no signs of tumor in any cavity of the body. Case 3 had left breast carcinoma. All conventional treatments failed. Her carcinoma metastases broadly and her marrow function was very poor. After 2 cycle treatments PET/CT scan showed PR. Conclusions: Primary clinical data shows that SDT with SF1 is well tolerated and has a significant therapeutic effect for some patients with advanced breast cancer. Even a terminally ill patient can be treated safely and effectively. Sonodynamic therapy with SF1 has significant merit for further investigation.

No significant financial relationships to disclose.

Source

SonneMed - Sonodynamic Therapy

The Tumoricidal Effect of Sonodynamic Therapy (SDT) on S-180

Integrative Cancer Therapies, Vol. 7, No. 2, 96-102 (2008)
DOI: 10.1177/1534735408319065

Sarcoma in Mice
Xiaohuai Wang, MD

Department of Oncology, Liu Hua Qiao Hospital, Guangzhou, P. R. China, tlewis@sonnemed.com

Thomas J. Lewis, PhD

SonneMed LLC, Boston, Massachusetts

Doug Mitchell, PhD

There are increasing data showing that sonodynamic therapy (SDT), which refers to a synergistic effect of drugs and ultrasound, is a promising new modality for cancer treatment. However, few clinical data on SDT have been published. One reason is the lack of suitable drugs for clinical SDT use. Recently a new sonosensitizing agent has been developed by SonneMed, LLC, referred to as SF1. In this study the effect of SDT with SF1 on S-180 sarcoma in mice was examined. The tumor bearing mice were allocated to the following groups: (1) sham-treatment (control, C); (2) ultrasound treatment (only ultrasound treatment, 1.2 mW/cm2 , without SF1, U); (3) SF1 treatment (SF1 20 mg/kg intraperitoneal [ip] without ultrasound treatment, S); and (4) SF1 + ultrasound treatment (SU). Following treatment, tumor volume was monitored. Tumor growth inhibition was seen only in group SU, and with increasing ultrasound intensity, the inhibitory effect was enhanced. Tumor growth inhibition was also visible even when covered by a barrier of bone. Pathological slices showed coagulated necrosis or metamorphic tissue with inflammatory reaction in the tumor taken from 2 to 36 hours after SDT. These data revealed that SDT with SF1 did inhibit growth of mouse S-180 sarcoma and the inhibitory effect was sound intensity dependent. SDT also induced some inflammation while it destroyed the tumor, indicative of a "vaccine" effect. SF1 shows great promise for clinical use in the future.

Key Words: photodynamic therapy • sonodynamic therapy • cancer • cancer therapy • tumor necrosis • tumoricidal • poryphrins • SonneMed • mouse S-180 sarcoma • anticancer

Source